KRAS G12D

Clinical trials for KRAS G12D explained in plain language.

Never miss a new study

Get alerted when new KRAS G12D trials appear

Sign up with your email to follow new studies for KRAS G12D, keep track of the ones that matter, and come back to a personal dashboard instead of checking manually.

Our safety recommendation!

By submitting, you agree to our Terms of use

Trials to join now! 6 Not yet recruiting 1 Not yet finished but already full! 2 Completed 1

New cancer vaccine targets 'Undruggable' KRAS mutations in early trial

Disease control Completed

This early-stage trial tested a new immunotherapy called ELI-002 in 25 people with pancreatic, colorectal, lung, and other cancers that have specific KRAS mutations. The treatment was given after standard therapy to target any remaining cancer cells and prevent recurrence. Resear…

Matched conditions: KRAS G12D

Phase: PHASE1 • Sponsor: Elicio Therapeutics • Aim: Disease control

Last updated Mar 30, 2026 14:31 UTC

KRAS G12D

Get alerted when new KRAS G12D trials appear

New cancer vaccine targets 'Undruggable' KRAS mutations in early trial